Stocks of Gilead Sciences, Inc. (NASDAQ:GILD) traded higher last session on Wall Street, up 0.16% to $67.65.
GILD stock price is now -2.94% away from the 50-day moving average and -10.60% away from the 200-day moving average. The market capitalization of the company currently stands at $84.28B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target reduced from $90 to $85, Maxim Group maintained Buy rating for Gilead Sciences, Inc. (NASDAQ: GILD). On April 24, 2024, HSBC Securities Upgraded its previous ‘Reduce’ rating to ‘Hold’ on the stock keeping its target price maintained at $69, while ‘Truist’ rates the stock as ‘Hold’
In other news, GILEAD SCIENCES, INC., 10% Owner bought 485,250 shares of the company’s stock on Apr 02 ’24. The stock was bought for $368,790 at an average price of $0.76. Upon completion of the transaction, the 10% Owner now directly owns 7,345,473 shares in the company, valued at $496.92 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 01 ’24, Chief Medical Officer Parsey Merdad sold 2,000 shares of the business’s stock. A total of $145,920 was realized by selling the stock at an average price of $72.96. This leaves the insider owning 96,304 shares of the company worth $6.51 million. A total of 0.10% of the company’s stock is owned by insiders.
During the past 12 months, Gilead Sciences, Inc. has had a low of $64.33 and a high of $87.86. As of last week, the company has a debt-to-equity ratio of 1.44, a current ratio of 1.08, and a quick ratio of 0.94.
According to the Drug Manufacturers – General Company, earnings per share came in at 1.34, missing analysts’ expectations of 1.64 by -0.3. This compares to $0.78 EPS in the same period last year. The net profit margin was 1.77% and return on equity was 2.51% for GILD. The company reported revenue of $6.69 billion for the quarter, compared to $6.35 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 5.26 percent. For the current quarter, analysts expect GILD to generate $6.7B in revenue.
